MTPConnect signs MoU with Medical Alley Association

By LabOnline Staff
Thursday, 05 October, 2017

Mtpconnnect medical alley

MTPConnect, the Medical Technologies, Biotechnologies and Pharmaceuticals Industry Growth Centre, has signed a memorandum of understanding (MoU) with the Medical Alley Association, a Minnesota-based organisation that enables health innovation and care organisations to successfully influence the evolution of health care.

The MoU was signed at the 2017 MedTech Conference, held last week in San Jose, by MTPConnect General Manager of Stakeholder Engagement Dr Alfredo Martinez-Coll and Medical Alley Association CEO Shaye Mandle. The two organisations seek to increase collaboration on activities that boost the biotechnology, pharmaceutical, health and medical technology sectors of both Australia and the US, planning to work together on activities such as providing introductions and in-market support in their respective jurisdictions, exchanging information on key issues and trends, supporting inbound and outbound missions, and delivering joint events and projects.

“The MedTech Conference … has provided the perfect platform for MTPConnect and Medical Alley to sign an MoU to align our two organisations and collaborate to strengthen the growth of our respective markets,” said Dr Martinez-Coll. “Medical Alley offers outstanding support to Minnesota’s health industry, and we look forward to forging a strong and fruitful relationship, opening further connections between the exciting innovations in our great countries.”

“Australia and Medical Alley have a history dating back to the development of the pacemaker,” added Mandle. “Our partnership today sets the stage for continuing to help patients live better, longer. We look forward to continued partnership with MTPConnect and the Australian medical technology community.”

MTPConnect led a delegation of 29 Australian companies, research organisations and industry bodies to the MedTech Conference to showcase Australia’s innovative medical technology companies and build inroads into international markets. CSIRO and Austrade presented to the international audience in a panel session titled ‘Why Australia’, highlighting Australia’s thriving medical technology, biotechnology and pharmaceutical ecosystem, generous incentive programs, strong credentials in medical devices and diagnostic development, and strong clinical trials sector.

Image caption: Dr Alfredo Martinez-Coll and Shaye Mandle signing the MoU.

Related News

Aphria ships cannabis oil to Australia for pain management trial

Canadian medical marijuana producer Aphria has completed its first shipment of cannabis oil to...

72 new genetic markers for breast cancer identified in global study

Researchers from 300 different institutions have collaborated on the world's biggest ever...

76 new types of antibiotic resistance genes found

Researchers have found 76 new types of antibiotic resistance genes by analysing large volumes of...

  • All content Copyright © 2017 Westwick-Farrow Pty Ltd